Brind.
  1. The FDA granted QIDP designation to Talicia, an FDA-approved rifabutin-based product, on August 18, 2025. Rick Scruggs is President and CCO of RedHill Biopharma Ltd.

Apotex acquired the Talicia business from RedHill Biopharma Ltd., which focuses on targeting H. pylori infection.

2 reports, 1 independent Updated Aug 31
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Apotex acquired the Talicia business from RedHill Biopharma Ltd., which focuses on targeting H. pylori infection.

Who's involved

What this event is mainly about
Apotex

Keep exploring

Part of

The FDA granted QIDP designation to Talicia, an FDA-approved rifabutin-based product, on August 18, 2025. Rick Scruggs is President and CCO of RedHill Biopharma Ltd. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story